Pharmaceutical Business Review Breaking News Headlines Today | Ground News

Pharmaceutical Business Review image

News from Pharmaceutical Business Review

All of today’s top news stories from Pharmaceutical Business Review. Get the full analysis behind how media bias impacts breaking news.

We’ve discovered 68 headlines written by Pharmaceutical Business Review during the past 3 months.

Ground News rates Pharmaceutical Business Review’s media bias as . . Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Pharmaceutical Business Review’s factuality rating is Unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Pharmaceutical Business Review

Where is Pharmaceutical Business Review located?Pharmaceutical Business Review's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Pharmaceutical Business Review News

Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders - Pipelinereview

Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders - Pipelinereview

TOKYO, Japan I December 25, 2024 I Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. (HQ: Chuo-Ku, Tokyo, Japan; “Astellas”) to explore new candidate compounds for targeted protein degraders. Axcelead DDP focuses on targeted protein degradation as the next generation of small-molecule drug discovery and prov…See the Story

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia - PressReach

Guangzhou · Guangzhou

Bio-Thera Solutions Partners with Tabuk Pharmaceuticals to Commercialize BAT2206, a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia - PressReach

GUANGZHOU, China, Dec. 24, 2024 /PRNewswire/ — Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company has partnered with Tabuk Pharmaceutical Manufacturing Company (a fully-owned subsidiary of Astra Industrial Group), a leading pharmaceutical company in the Middle East and North Africa (MENA) region, for BAT2206, i…See the Story

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Art · Switzerland

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Additional funding awarded following successful drug candidate nomination USD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal …See the Story

Latest News Stories

You've scrolled to the bottom of the feed, there are no more stories.

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc